Manufacturer

Country

Certificates

Registration Date	16 Nov 2016
Share

Actemra

(0)

Medicine Pharmaceuticals Product Number : 50242-138-01

Interleukin Inhibitor

Drug Information

Generic

tocilizumab

NDC Code

50242-138-01

Drug Class

Interleukin inhibitors

Therapeutic Class

Immunomodulator

Dosage form

Solution

Route of Administration

Intravenous Injection

Therapeutic Area

1.rheumatoid arthritis

Indication

"Actemra® (tocilizumab) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Polyarticular Juvenile Idiopathic Arthritis (PJIA) Actemra® (tocilizumab) is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. Systemic Juvenile Idiopathic Arthritis (SJIA) Actemra® (tocilizumab) is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older."